ESMO 2019: Invited Discussant: The CARD Trial – Cabazitaxel as Third Line Therapy in Metastatic Castration-Resistant Prostate Cancer

Barcelona, Spain (UroToday.com) In this discussion of the CARD trial of cabazitaxel as third line therapy in metastatic castration-resistant prostate cancer (mCRPC), Silke Gillessen, MD, began by laying out the therapeutic landscape of mCRPC, using this imagery to highlight what happens after up-front anti-androgen therapy and docetaxel chemotherapy, because it is less clear what the […]

ESMO 2019: Invited Discussant: How Do the Results of IMvigor130 Change Things in Bladder Cancer?

Barcelona, Spain (UroToday.com) Following the presentation of IMvigor130 assessing atezolizumab in combination with platinum-based chemotherapy in the first-line setting for metastatic urothelial carcinoma, Professor Thomas Powles provided an invited discussion of these findings. He notes that until recently, the chemotherapy paradigm of treatment was as follows: If patients were eligible for cisplatin chemotherapy – gemcitabine/cisplatin (median overall […]

ESMO 2019: Treatment of Pelvic Node-Positive Prostate Cancer: Systemic Treatment: The Role of Chemotherapy and Androgen Receptor Targeted Therapy

Barcelona, Spain (UroToday.com) At the 2019 European Society for Medical Oncology annual meeting (ESMO), experts gathered from urology, radiation oncology, and medical oncology to discuss the clinical management of pelvic node-positive (cN+) prostate cancer. Dr. Silke Gillessen, discussed the role of chemotherapy and androgen receptor targeted therapy (ARTT) in managing pelvic node-positive prostate cancer. The session […]

ESMO 2019: Invited Discussant – Phase 3 PROfound Study for Metastatic Castration-resistant Prostate Cancer (LBA12)

Barcelona, Spain (UroToday.com) Following the presentation of PROfound, Dr. Eleni Efstathiou provided an invited discussion of this study. Dr. Efstathiou notes that this is the first targeted therapy Phase III prostate cancer trial to deliver positive results. Patients with germline BRCA mutation carriers have a poor prognosis and do not respond well to cytotoxic therapies, thus […]

Multiparametric Cystoscopy for Detection of Bladder Cancer Using Real-time Multispectral Imaging.

Various imaging modalities can be used in addition to white light (WL) to improve detection of bladder cancer (BC). To use real-time multispectral imaging (rMSI) during urethrocystoscopy to combine different imaging modalities to achieve multiparametric cystoscopy (MPC). The rMSI system consisted of a camera with a spectral filter, a multi-LED light source, a microcontroller, and […]

Prediction of complication related death after radical cystectomy for bladder cancer with machine learning methodology.

Purpose: To create a pre-operatively usable tool to identify patients at high risk of early death (within 90 days post-operatively) after radical cystectomy and to assess potential risk factors for post-operative and surgery related mortality. Materials and methods: Material consists of 1099 consecutive radical cystectomy (RC) patients operated at 16 different hospitals in Finland 2005-2014. Machine […]

Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.

Bladder cancer is the most frequently occurring tumour of the urinary system. Ta, T1 tumours and carcinoma in situ (CIS) are grouped as non-muscle invasive bladder cancer (NMIBC), which can be effectively treated by transurethral resection of bladder tumour (TURBT). There are limitations to the visualisation of tumours with conventional TURBT using white light illumination […]

Remarkable effect of presurgical nivolumab on originally inoperable papillary renal cell carcinoma with tumor thrombus in inferior vena cava.

For the long-term survival of a patient with renal cell carcinoma and a vena cava tumor thrombus, total resection is desired: inoperable patients are sometimes treated with drugs. The effect of the presurgical use of nivolumab, an anti-programmed cell death 1 (PD-1) antibody drug, has been described. Our patient had inoperable renal cancer with an […]

LINC00461 affects the survival of patients with renal cell carcinoma by acting as a competing endogenous RNA for microRNA‑942.

The present study aimed to investigate the potential mechanisms of human miR‑942 in the sunitinib‑resistance of renal cell carcinoma (RCC). A sunitinib‑resistant OS‑RC‑2 cell line was established by continuous exposure to increasing concentrations of sunitinib for ~12 weeks. The expression levels of four miRNAs were determined by reverse transcription‑quantitative (RT‑q)PCR. miR‑942 mimics were transfected into OS‑RC‑2 […]

Interleukin4Rα (IL4Rα) and IL13Rα1 Are Associated with the Progress of Renal Cell Carcinoma through Janus Kinase 2 (JAK2)/Forkhead Box O3 (FOXO3) Pathways.

Specific kinds of interleukin (IL) receptors are known to mediate lymphocyte proliferation and survival. However, recent reports have suggested that the high expression of IL4Rα and IL13Rα1 in tumor tissue might be associated with tumorigenesis in several kinds of tumor. We found that a significant association between mRNA level of IL4Rα or IL13Rα1 and the […]

X